Difference between revisions of "Amatuximab (MORAb-009)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Mesothelioma" to "Malignant pleural mesothelioma") |
||
Line 3: | Line 3: | ||
==Preliminary data== | ==Preliminary data== | ||
− | ===[[ | + | ===[[Malignant pleural mesothelioma]]=== |
# Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. Epub 2014 Sep 17. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4252585/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25231400 PubMed] | # Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. Epub 2014 Sep 17. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4252585/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25231400 PubMed] | ||
Revision as of 16:55, 1 May 2022
Mechanism of action
From the NCI Drug Dictionary: A humanized IgG1 monoclonal antibody directed against human mesothelin with potential antineoplastic activity. Amatuximab binds to mesothelin, triggering an antibody dependent cellular cytotoxicity (ADCC)-mediated host immune response against mesothelin-expressing tumor cells, which may result in tumor cell lysis. Mesothelin, a 40kDa cell surface glycoprotein, is overexpressed in several human tumors, including mesothelioma and ovarian and pancreatic adenocarcinomas.
Preliminary data
Malignant pleural mesothelioma
- Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. Epub 2014 Sep 17. link to PMC article PubMed
Also known as
- Code name: MORAb-009